FY2028 Earnings Estimate for Disc Medicine Issued By Wedbush

Disc Medicine, Inc. (NASDAQ:IRON) – Research analysts at Wedbush lifted their FY2028 earnings estimates for shares of Disc Medicine in a research report issued on Tuesday, January 21st. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of $7.51 per share for the year, up from their previous estimate of $7.04. Wedbush currently has a “Outperform” rating and a $90.00 target price on the stock. The consensus estimate for Disc Medicine’s current full-year earnings is ($4.07) per share. Wedbush also issued estimates for Disc Medicine’s FY2029 earnings at $12.05 EPS.

Disc Medicine (NASDAQ:IRON) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.89) earnings per share for the quarter, beating the consensus estimate of ($1.04) by $0.15.

Several other research firms have also weighed in on IRON. Scotiabank boosted their target price on shares of Disc Medicine from $62.00 to $70.00 and gave the company a “sector outperform” rating in a research note on Tuesday, November 5th. Morgan Stanley raised shares of Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 price objective for the company in a research report on Tuesday, November 5th. HC Wainwright restated a “buy” rating and issued a $118.00 target price on shares of Disc Medicine in a research note on Tuesday. Stifel Nicolaus increased their price target on Disc Medicine from $79.00 to $90.00 and gave the stock a “buy” rating in a research report on Tuesday, December 10th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $85.00 price objective on shares of Disc Medicine in a research report on Tuesday, October 15th. Nine research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $88.20.

Disc Medicine Trading Up 3.9 %

Shares of NASDAQ IRON opened at $60.52 on Wednesday. The business has a 50 day simple moving average of $62.82 and a 200-day simple moving average of $53.66. Disc Medicine has a twelve month low of $25.60 and a twelve month high of $77.60.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Wellington Management Group LLP lifted its position in shares of Disc Medicine by 4.8% in the 3rd quarter. Wellington Management Group LLP now owns 1,840,226 shares of the company’s stock valued at $90,429,000 after acquiring an additional 83,731 shares in the last quarter. Frazier Life Sciences Management L.P. raised its stake in Disc Medicine by 123.5% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 1,754,834 shares of the company’s stock valued at $79,090,000 after purchasing an additional 969,834 shares during the period. Deerfield Management Company L.P. Series C lifted its holdings in shares of Disc Medicine by 53.8% in the second quarter. Deerfield Management Company L.P. Series C now owns 1,023,265 shares of the company’s stock valued at $46,119,000 after purchasing an additional 357,730 shares in the last quarter. Logos Global Management LP acquired a new stake in shares of Disc Medicine in the second quarter worth $41,690,000. Finally, State Street Corp grew its holdings in shares of Disc Medicine by 39.7% during the third quarter. State Street Corp now owns 827,910 shares of the company’s stock valued at $40,683,000 after buying an additional 235,115 shares in the last quarter. 83.70% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Disc Medicine

In other news, insider Rahul Khara sold 7,500 shares of the business’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $62.75, for a total transaction of $470,625.00. Following the sale, the insider now directly owns 14,035 shares of the company’s stock, valued at $880,696.25. The trade was a 34.83 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider William Jacob Savage sold 9,158 shares of Disc Medicine stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $59.64, for a total value of $546,183.12. Following the completion of the transaction, the insider now directly owns 40,405 shares in the company, valued at $2,409,754.20. This represents a 18.48 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 85,758 shares of company stock worth $5,400,990 over the last quarter. 4.24% of the stock is currently owned by company insiders.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.